UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)

Annals of oncology, 2018-10, Vol.29, p.viii119-viii119

2018

Volltextzugriff (PDF)

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine

Journal of molecular and cellular cardiology, 2009-08, Vol.47 (2), p.326-334

2009

Volltextzugriff (PDF)

308P Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases

Annals of oncology, 2020-09, Vol.31, p.S365-S366

2020

Volltextzugriff (PDF)

169P Trastuzumab use among patients with HER2-positive metastatic breast cancer in an electronic health records database

Annals of oncology, 2020-05, Vol.31, p.S76-S77

2020

Volltextzugriff (PDF)

Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

Annals of oncology, 2019-10, Vol.30, p.v129

2019

Volltextzugriff (PDF)

356P - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

Annals of oncology, 2019-10, Vol.30, p.v129-v129

2019

Volltextzugriff (PDF)

356PUse of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

The nitrodibenzofuran chromophore: a new caging group for ultra-efficient photolysis in living cells

Nature methods, 2006-01, Vol.3 (1), p.35-40

2006

Volltextzugriff (PDF)

365TiPSAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-12-10

2017

Volltextzugriff (PDF)

Abstract P4-21-07: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-07

2017

Volltextzugriff (PDF)

Abstract P4-21-04: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-04

2017

Volltextzugriff (PDF)

The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

European journal of cancer (1990), 2018-04, Vol.92, p.S105-S106

2018

Volltextzugriff (PDF)

370 (PB-165) - The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

European journal of cancer (1990), 2018-04, Vol.92, p.S105-S106

2018

Volltextzugriff (PDF)

Paradoxical SR Ca2+ release in guinea‐pig cardiac myocytes after β‐adrenergic stimulation revealed by two‐photon photolysis of caged Ca2

The Journal of physiology, 2005-06, Vol.565 (3), p.801-813

2005

Volltextzugriff (PDF)

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Annals of oncology, 2019-05, Vol.30 (5), p.766

2019

Volltextzugriff (PDF)

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca 2+ overload and inhibited by ranolazine

Journal of molecular and cellular cardiology, 2009, Vol.47 (2), p.326-334

2009

Volltextzugriff (PDF)

Rubidium Chloride Fuses Split Circadian Activity Rhythms in Hamsters Housed in Bright Constant Light

Chronobiology international, 1994, Vol.11 (2), p.65-71

1994

Volltextzugriff (PDF)

Contribution a l'etude du gros rein polykystique et son operation

Lindegger, Gaspard

1896

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(18)
Dissertationen
(1)

Sprache

Englisch
(18)
Französisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

SAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine

308P Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases

169P Trastuzumab use among patients with HER2-positive metastatic breast cancer in an electronic health records database

Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

356P - Use of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

356PUse of trastuzumab emtansine (T-DM1; K) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

The nitrodibenzofuran chromophore: a new caging group for ultra-efficient photolysis in living cells

365TiPSAMANTHA: A European registry study to prospectively observe treatment patterns and outcomes in participants with HER2-positive unresectable locally advanced (LA) or metastatic breast cancer (mBC)

Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study

Abstract P4-21-07: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study

Abstract P4-21-04: Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

Paradoxical SR Ca2+ release in guinea‐pig cardiac myocytes after β‐adrenergic stimulation revealed by two‐photon photolysis of caged Ca2

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Diastolic transient inward current in long QT syndrome type 3 is caused by Ca 2+ overload and inhibited by ranolazine

Rubidium Chloride Fuses Split Circadian Activity Rhythms in Hamsters Housed in Bright Constant Light

Contribution a l'etude du gros rein polykystique et son operation

Aktive Filter

Suchergebnisse filtern